This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 May;24(6):694-695.

doi: 10.1177/1352458518771846. Epub 2018 Apr 24.

Comparisons of therapies in different scenarios help complete the puzzle

Tomas Kalincik¹

Affiliations

Affiliation

¹ CORe, Department of Medicine, The University of Melbourne, Parkville, VIC, Australia/Department of Neurology, The Royal Melbourne Hospital, Parkville, VIC, Australia.

PMID: 29685060
DOI: 10.1177/1352458518771846

Editorial

Comparisons of therapies in different scenarios help complete the puzzle

Tomas Kalincik. Mult Scler. 2018 May.

. 2018 May;24(6):694-695.

doi: 10.1177/1352458518771846. Epub 2018 Apr 24.

Author

Tomas Kalincik¹

Affiliation

¹ CORe, Department of Medicine, The University of Melbourne, Parkville, VIC, Australia/Department of Neurology, The Royal Melbourne Hospital, Parkville, VIC, Australia.

PMID: 29685060
DOI: 10.1177/1352458518771846

No abstract available

PubMed Disclaimer

Comment on

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö. Lorscheider J, et al. Mult Scler. 2018 May;24(6):777-785. doi: 10.1177/1352458518768433. Epub 2018 Apr 24. Mult Scler. 2018. PMID: 29685071

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information